Hannah Linden, MD, Highlights AMEERA-1 for ER+/HER2- mBC

from Oncology Learning Network · host HMP Global

Dr Linden shares encouraging results from the AMEERA-1 trial on SAR439859, an oral estrogen receptor degrader, for ER+/HER2- metastatic breast cancer, presented at the virtual 2020 SABCS Annual Meeting.

Episode metadata supplied by the publisher feed · Published Dec 16, 2020

Embed this episode

Attribution link and audio player

Ready to play

Hannah Linden, MD, Highlights AMEERA-1 for ER+/HER2- mBC

0:00 8:20

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Learning Network?

This episode is 8 minutes long.

When was this Oncology Learning Network episode published?

This episode was published on December 16, 2020.

Can I download this Oncology Learning Network episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!